Skandinaviska Enskilda Banken AB publ Sells 16,900 Shares of Halozyme Therapeutics, Inc. $HALO

Skandinaviska Enskilda Banken AB publ lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 24.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 51,000 shares of the biopharmaceutical company’s stock after selling 16,900 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Halozyme Therapeutics were worth $2,652,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Wealth Preservation Advisors LLC purchased a new position in Halozyme Therapeutics during the first quarter worth $32,000. SVB Wealth LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $33,000. Employees Retirement System of Texas purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $34,000. Brooklyn Investment Group grew its holdings in Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 670 shares during the last quarter. Finally, Asset Management One Co. Ltd. purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth about $98,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of several recent analyst reports. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price on the stock in a research note on Tuesday, October 14th. Benchmark boosted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Halozyme Therapeutics in a report on Wednesday, November 19th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $75.10.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $68.10 on Tuesday. The firm has a market cap of $8.01 billion, a P/E ratio of 15.58, a P/E/G ratio of 0.35 and a beta of 1.18. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12 month low of $46.26 and a 12 month high of $79.50. The stock’s fifty day moving average price is $69.05 and its 200-day moving average price is $64.09.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. During the same period in the prior year, the firm earned $1.27 earnings per share. The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $71.60, for a total value of $59,356.40. Following the completion of the transaction, the director owned 42,123 shares of the company’s stock, valued at $3,016,006.80. The trade was a 1.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Nicole Labrosse sold 2,227 shares of the stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the sale, the chief financial officer directly owned 22,079 shares in the company, valued at $1,721,058.05. This trade represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 123,625 shares of company stock valued at $8,935,527. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.